BCG 016
Alternative Names: BCG-016Latest Information Update: 05 Jul 2024
At a glance
- Originator Beijing Biocytogen
- Class Antineoplastics; Bispecific antibodies; Drug conjugates; Immunoconjugates
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 18 Jun 2024 BCG 016 is available for licensing as of 18 Jun 2024. https://www.biocytogen.jp/technology/detail/bispecific-ADC.html (Beijing Biocytogen website; June 2024)
- 05 Apr 2024 Preclinical trials in Solid tumours in China (Parenteral) prior to April 2023
- 05 Apr 2024 Pharmacodynamics data from the preclinical data in Solid tumours presented at the 115th Annual Meeting of the American Association for Cancer Research 2024 (AACR-2024)